• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics.由C9orf72基因中六核苷酸重复扩增引起的肌萎缩侧索硬化症:从遗传学到治疗学
Lancet Neurol. 2025 Mar;24(3):261-274. doi: 10.1016/S1474-4422(25)00026-2.
2
Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.C9orf72 肌萎缩侧索硬化症/额颞叶痴呆的发病机制和治疗进展。
Neurotherapeutics. 2019 Oct;16(4):1115-1132. doi: 10.1007/s13311-019-00797-2.
3
Molecular Mechanisms of Neurodegeneration Related to Hexanucleotide Repeat Expansion.与六核苷酸重复序列扩增相关的神经退行性变的分子机制
Behav Neurol. 2019 Jan 15;2019:2909168. doi: 10.1155/2019/2909168. eCollection 2019.
4
Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.携带 C9ORF72 基因 GGGGCC 六核苷酸重复扩展的家族性肌萎缩侧索硬化症患者的临床特征。
Brain. 2012 Mar;135(Pt 3):784-93. doi: 10.1093/brain/awr366.
5
The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions.C9ORF72 六核苷酸重复扩展的临床和病理学表型。
Brain. 2012 Mar;135(Pt 3):723-35. doi: 10.1093/brain/awr353. Epub 2012 Feb 1.
6
Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis.感码多聚-GR 二肽重复蛋白与神经退行性变相关,并且在 C9orf72 肌萎缩侧索硬化症重复扩展的树突中与 TDP-43 独特地共定位。
Acta Neuropathol. 2018 Mar;135(3):459-474. doi: 10.1007/s00401-017-1793-8. Epub 2017 Dec 1.
7
C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels.C9orf72 肌萎缩侧索硬化症-额颞叶变性:多个层面自噬溶酶体途径失调的最新证据。
Autophagy. 2021 Nov;17(11):3306-3322. doi: 10.1080/15548627.2021.1872189. Epub 2021 Feb 26.
8
Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs.靶向含GGGGCC的RNA的反义寡核苷酸可减轻C9ORF72中与肌萎缩侧索硬化症/额颞叶痴呆相关的重复序列扩增导致的毒性。
Neuron. 2016 May 4;90(3):535-50. doi: 10.1016/j.neuron.2016.04.006. Epub 2016 Apr 21.
9
RNA-mediated toxicity in C9orf72 ALS and FTD.C9orf72 肌萎缩侧索硬化症和额颞叶痴呆的 RNA 介导毒性。
Neurobiol Dis. 2020 Nov;145:105055. doi: 10.1016/j.nbd.2020.105055. Epub 2020 Aug 21.
10
Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions.C9orf72重复序列扩增导致多种含RNA识别基序的蛋白质被隔离。
Brain. 2014 Jul;137(Pt 7):2040-51. doi: 10.1093/brain/awu120. Epub 2014 May 27.

引用本文的文献

1
Pharmacological effects, molecular mechanisms and strategies to improve bioavailability of curcumin in the treatment of neurodegenerative diseases.姜黄素在神经退行性疾病治疗中的药理作用、分子机制及提高生物利用度的策略
Front Pharmacol. 2025 Jul 10;16:1625821. doi: 10.3389/fphar.2025.1625821. eCollection 2025.
2
Therapeutic Approaches for C9ORF72-Related ALS: Current Strategies and Future Horizons.C9ORF72相关肌萎缩侧索硬化症的治疗方法:当前策略与未来展望
Int J Mol Sci. 2025 Jun 28;26(13):6268. doi: 10.3390/ijms26136268.
3
Dynamics of Onset and Progression in Amyotrophic Lateral Sclerosis.肌萎缩侧索硬化症的发病与进展动态
Brain Sci. 2025 Jun 3;15(6):601. doi: 10.3390/brainsci15060601.
4
Pathophysiology, Clinical Heterogeneity, and Therapeutic Advances in Amyotrophic Lateral Sclerosis: A Comprehensive Review of Molecular Mechanisms, Diagnostic Challenges, and Multidisciplinary Management Strategies.肌萎缩侧索硬化症的病理生理学、临床异质性及治疗进展:分子机制、诊断挑战与多学科管理策略的全面综述
Life (Basel). 2025 Apr 14;15(4):647. doi: 10.3390/life15040647.

本文引用的文献

1
Oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling and therapeutic implications.肌萎缩侧索硬化症的寡基因结构具有基因检测、咨询和治疗意义。
J Neurol Neurosurg Psychiatry. 2025 Feb 13. doi: 10.1136/jnnp-2024-335364.
2
Dual-targeting CRISPR-CasRx reduces C9orf72 ALS/FTD sense and antisense repeat RNAs in vitro and in vivo.双靶点CRISPR-CasRx在体外和体内均可减少C9orf72肌萎缩侧索硬化症/额颞叶痴呆的正义和反义重复RNA。
Nat Commun. 2025 Jan 8;16(1):459. doi: 10.1038/s41467-024-55550-x.
3
repeat expansion creates the unstable folate-sensitive fragile site FRA9A.重复扩增产生不稳定的叶酸敏感脆性位点FRA9A。
NAR Mol Med. 2024 Nov 12;1(4):ugae019. doi: 10.1093/narmme/ugae019. eCollection 2024 Oct.
4
C9orf72 poly-PR forms anisotropic condensates causative of nuclear TDP-43 pathology.C9orf72 多聚脯氨酸形成各向异性凝聚物,导致核 TDP - 43 病理学变化。
iScience. 2024 Sep 14;27(10):110937. doi: 10.1016/j.isci.2024.110937. eCollection 2024 Oct 18.
5
Increased frequency of repeat expansion mutations across different populations.在不同人群中,重复扩展突变的频率增加。
Nat Med. 2024 Nov;30(11):3357-3368. doi: 10.1038/s41591-024-03190-5. Epub 2024 Oct 1.
6
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study.在携带 C9orf72 基因突变的肌萎缩侧索硬化症成人患者中,反义寡核苷酸 BIIB078 的安全性、耐受性和药代动力学:一项 I 期、随机、双盲、安慰剂对照、递增剂量的研究。
Lancet Neurol. 2024 Sep;23(9):901-912. doi: 10.1016/S1474-4422(24)00216-3. Epub 2024 Jul 23.
7
Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS.血浆细胞外囊泡 tau 和 TDP-43 作为 FTD 和 ALS 的诊断生物标志物。
Nat Med. 2024 Jun;30(6):1771-1783. doi: 10.1038/s41591-024-02937-4. Epub 2024 Jun 18.
8
Failure of C9orf72 sense repeat-targeting antisense oligonucleotides: lessons learned and the path forward.靶向C9orf72正义重复序列的反义寡核苷酸治疗失败:经验教训与未来方向
Brain. 2024 Aug 1;147(8):2607-2609. doi: 10.1093/brain/awae168.
9
Neurofilaments as biomarkers in neurological disorders - towards clinical application.神经丝作为神经紊乱的生物标志物——迈向临床应用。
Nat Rev Neurol. 2024 May;20(5):269-287. doi: 10.1038/s41582-024-00955-x. Epub 2024 Apr 12.
10
Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial.二甲氨乙泼尼龙在 C9orf72 肌萎缩侧索硬化症中的应用:一项随机 2a 期临床试验。
Brain. 2024 Sep 3;147(9):2998-3008. doi: 10.1093/brain/awae109.

由C9orf72基因中六核苷酸重复扩增引起的肌萎缩侧索硬化症:从遗传学到治疗学

Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics.

作者信息

Mizielinska Sarah, Hautbergue Guillaume M, Gendron Tania F, van Blitterswijk Marka, Hardiman Orla, Ravits John, Isaacs Adrian M, Rademakers Rosa

机构信息

UK Dementia Research Institute at King's College London, London, UK; Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.

Sheffield Institute for Translational Neuroscience (SITraN), Neuroscience Institute, and Healthy Lifespan Institute (HELSI), University of Sheffield, Sheffield, UK.

出版信息

Lancet Neurol. 2025 Mar;24(3):261-274. doi: 10.1016/S1474-4422(25)00026-2.

DOI:10.1016/S1474-4422(25)00026-2
PMID:39986312
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12010636/
Abstract

GGGGCC repeat expansions in C9orf72 are a common genetic cause of amyotrophic lateral sclerosis in people of European ancestry; however, substantial variability in the penetrance of the mutation, age at disease onset, and clinical presentation can complicate diagnosis and prognosis. The repeat expansion is bidirectionally transcribed in the sense and antisense directions into repetitive RNAs and translated into dipeptide repeat proteins, and both accumulate in the cortex, cerebellum, and the spinal cord. Furthermore, neuropathological aggregates of phosphorylated TDP-43 are observed in motor cortex and other cortical regions, and in the spinal cord of patients at autopsy. C9orf72 repeat expansions can also cause frontotemporal dementia. The GGGGCC repeat induces a complex interplay of loss-of-function and gain-of-function pathological mechanisms. Clinical trials using antisense oligonucleotides to target the GGGGCC repeat RNA have not been successful, potentially because they only target a single gain-of-function mechanism. Novel therapeutic approaches targeting the DNA repeat expansion, multiple repeat-derived RNA species, or downstream targets of TDP-43 dysfunction are, however, on the horizon, together with the development of diagnostic and prognostic biomarkers.

摘要

C9orf72基因中的GGGGCC重复序列扩增是欧洲血统人群肌萎缩侧索硬化症常见的遗传病因;然而,该突变的外显率、发病年龄和临床表现存在很大差异,会使诊断和预后变得复杂。这种重复序列扩增会以正向和反向双向转录为重复RNA,并翻译为二肽重复蛋白,二者都会在大脑皮层、小脑和脊髓中积累。此外,在运动皮层和其他皮质区域以及尸检患者的脊髓中观察到磷酸化TDP - 43的神经病理聚集体。C9orf72重复序列扩增也可导致额颞叶痴呆。GGGGCC重复序列引发了功能丧失和功能获得病理机制的复杂相互作用。使用反义寡核苷酸靶向GGGGCC重复RNA的临床试验尚未成功,这可能是因为它们仅针对单一的功能获得机制。然而,随着诊断和预后生物标志物的发展,针对DNA重复序列扩增、多种重复衍生的RNA种类或TDP - 43功能障碍下游靶点的新型治疗方法即将出现。